We were fortunate to meet with MDS Congress Scientific Program Committee member, Antonio Strafella (Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada) who spoke to us about imaging biomarkers of cognitive decline in Parkinson’s disease.
1. What is known about the pathological processes underlying cognitive decline in Parkinson’s disease (PD)? (0:05)
2. What neuroimaging biomarkers appear useful in this setting? (1:40)
3. What are the most promising CSF biomarkers of cognitive decline in PD? (3:18)
4. What genetic factors affect the risk of cognitive decline in patients with PD? (4:17)
5. What further research is needed before these biomarkers enter clinical use? (5:44)
Speaker disclosure: Antonio P Strafella has received funding from the Canada Research Chairs Program (CRCP), Canadian Institutes of Health Research (CIHR), National Parkinson Foundation (NPF), Parkinson Disease Foundation (PDF), Parkinson Canada, Ontario Gambling Association, Tourette Syndrome Association (TSA), Brain Canada, Weston Brain Institute, and honoraria from GE Healthcare Canada Ltd.
Filmed at the International Congress of Parkinson’s Disease and Movement Disorders (MDS), Nice, France, September 2019.
Share this Video
Related Videos In Parkinson's Disease
Francisco Cardoso: International Parkinson and Movement Disorder Society (MDS) – President update
The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals, who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control. touchNEUROLOGY caught up with the MDS President, Prof. Francisco Cardoso, to discuss the upcoming […]
Angelo Antonini, AD/PD 2022: Key clinical highlights in movement disorders and Parkinson’s disease
Prof. Angelo Antonini (Professor of Neurology, University of Padua, Padua, Italy) discusses the key clinical highlights and hot topics in movement disorders and Parkinson’s disease. Questions: What are the key clinical highlights from the past year in the field of movement disorders and Parkinson’s disease? Disclosures: Prof. Angelo Antonini is a consultant for AbbVie, Bial, […]
Angelo Antonini, AD/PD 2022: α-Synuclein seeding activity in gastrointestinal biopsies of Parkinson’s disease patients
Gastrointestinal dysfunctions represent one of the main non-motor symptoms in Parksinon’s disease (PD). Prof. Angelo Antonini (Professor of Neurology, University of Padua, Padua, Italy) discusses a study that investigated α-Synuclein seeding activity in stomach-duodenum biopsies of PD patients by real-time quaking induced conversion (RT-QuIC) assay. The results suggest a deeper investigation in detection of α-Synuclein […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!